A low-dose cytarabine, aclarubicin and granulocyte colony-stimulating factor priming regimen versus a daunorubicin plus cytarabine regimen as induction therapy for older patients with acute myeloid leukemia: A propensity score analysis
详细信息 查看全文
- 作者：Daisuke Minakata ; Shin-ichiro Fujiwara ; Shoko Ito ; Kiyomi Mashima ; Kento Umino ; Hirofumi Nakano ; Yasufumi Kawasaki ; Miyuki Sugimoto ; Ryoko Yamasaki ; Chihiro Yamamoto ; Masahiro Ashizawa ; Kaoru Hatano ; Kiyoshi Okazuka ; Kazuya Sato ; Iekuni Oh ; Ken Ohmine ; Takahiro Suzuki ; Kazuo Muroi ; Yoshinobu Kanda ; ycanda-tky@umin.ac.jp" class="auth_mail" title="E-mail the corresponding author
- 关键词：Acute myeloid leukemia ; Older patients ; Propensity score ; Induction therapy
- 刊名：Leukemia Research
- 出版年：2016
- 出版时间：March 2016
- 年：2016
- 卷：42
- 期：Complete
- 页码：82-87
- 全文大小：856 K
文摘
- •
We compared the efficacy of the DNR-AraC regimen to that of the CAG regimen.
- •
We calculated the propensity score for selecting the CAG regimen.
- •
We compared the two groups after stratification according to the propensity score.
- •
Intensive induction therapy should be performed for fit elderly patients with AML.
- •
Less-intensive therapy is sufficient for patients with higher age, MRC, lower WBC.